Please Scroll Down to See Forums Below
Anyone run Clen while on a cycle?
- Thread starter Deterass
- Start date
DANABOLIC55
New member
yes.
mrflexdiesel
New member
Why couldn't you bro? If you're trying to cut up a little while on gear and dieting it would be great to add. I would go with a 2 week on, and 2 week off rotating fashion for best results unless you have accsess to Ketotifen than you can run longer. Also, has been said to work well for some post cycle to help performance and retain lean muscle mass. This has been debated though.
awittyusername
New member
Good question.
J
Juice Authority
Guest
I'd say clen works to preserve muscle while burning fat.
Arch Phys Med Rehabil. 2001 Jul;82(7):930-4. Related Articles, Links
Clenbuterol in the prevention of muscle atrophy: a study of hindlimb-unweighted rats.
Herrera NM Jr, Zimmerman AN, Dykstra DD, Thompson LV.
Department of Physical Medicine and Rehabilitation, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
OBJECTIVE: To determine whether the administration of clenbuterol, a beta2-adrenergic agonist, prevents loss of muscle mass during a period of imposed inactivity. DESIGN: Randomized trial. SETTING: Basic laboratory research. ANIMALS: Thirty Fischer 344 Brown Norway F1 Hybrid rats, 12 and 30 months of age. INTERVENTIONS: The rats were randomly assigned to a control group, or to 1 of 2 experimental groups: hindlimb unweighted for 2 weeks (HU-2), or hindlimb unweighted with daily injections of clenbuterol for 2 weeks (HU-2Cl). MAIN OUTCOME MEASURES: Muscle mass weighed in milligrams and single fiber cross-sectional area histochemically evaluated. RESULTS: In both age groups, the HU-2 animals had greater muscle atrophy (decrease in muscle mass) in the soleus muscle than the extensor digitorum longus (EDL) muscle. In the HU-2Cl groups, the decline in muscle mass of both the soleus and EDL muscles was attenuated by about 4% to 20%. In the HU-2 group, single fiber cross-sectional area decreased for both fiber types (type I, 20%-40%; type II, 37%-50%) in both age groups. Clenbuterol retarded the inactivity-induced decline in single fiber cross-sectional area by 12% to 50%. In the EDL muscles of the HU-2Cl group, we found hypertrophy in both fiber types in the 30-month-old animals and in type I fibers in the 12-month-old animals. CONCLUSIONS: Clenbuterol attenuated the decrease in muscle mass and single fiber cross-sectional area in both age groups. By preventing the loss of muscle mass, clenbuterol administered early in rehabilitation may benefit severely debilitated patients imposed by inactivity. The attenuated muscle atrophy found with clenbuterol in the present study provides cellular evidence for the reported change in muscle strength after its administration after knee surgery. Thus, the administration of clenbuterol may lead to a more rapid rate of rehabilitation. Copyright 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 11441380 [PubMed - indexed for MEDLINE]
Arch Phys Med Rehabil. 2001 Jul;82(7):930-4. Related Articles, Links
Clenbuterol in the prevention of muscle atrophy: a study of hindlimb-unweighted rats.
Herrera NM Jr, Zimmerman AN, Dykstra DD, Thompson LV.
Department of Physical Medicine and Rehabilitation, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
OBJECTIVE: To determine whether the administration of clenbuterol, a beta2-adrenergic agonist, prevents loss of muscle mass during a period of imposed inactivity. DESIGN: Randomized trial. SETTING: Basic laboratory research. ANIMALS: Thirty Fischer 344 Brown Norway F1 Hybrid rats, 12 and 30 months of age. INTERVENTIONS: The rats were randomly assigned to a control group, or to 1 of 2 experimental groups: hindlimb unweighted for 2 weeks (HU-2), or hindlimb unweighted with daily injections of clenbuterol for 2 weeks (HU-2Cl). MAIN OUTCOME MEASURES: Muscle mass weighed in milligrams and single fiber cross-sectional area histochemically evaluated. RESULTS: In both age groups, the HU-2 animals had greater muscle atrophy (decrease in muscle mass) in the soleus muscle than the extensor digitorum longus (EDL) muscle. In the HU-2Cl groups, the decline in muscle mass of both the soleus and EDL muscles was attenuated by about 4% to 20%. In the HU-2 group, single fiber cross-sectional area decreased for both fiber types (type I, 20%-40%; type II, 37%-50%) in both age groups. Clenbuterol retarded the inactivity-induced decline in single fiber cross-sectional area by 12% to 50%. In the EDL muscles of the HU-2Cl group, we found hypertrophy in both fiber types in the 30-month-old animals and in type I fibers in the 12-month-old animals. CONCLUSIONS: Clenbuterol attenuated the decrease in muscle mass and single fiber cross-sectional area in both age groups. By preventing the loss of muscle mass, clenbuterol administered early in rehabilitation may benefit severely debilitated patients imposed by inactivity. The attenuated muscle atrophy found with clenbuterol in the present study provides cellular evidence for the reported change in muscle strength after its administration after knee surgery. Thus, the administration of clenbuterol may lead to a more rapid rate of rehabilitation. Copyright 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 11441380 [PubMed - indexed for MEDLINE]
rjl296
New member
unfortunatley that study was done on rate, and not humans.
to quote Dr. M from musclenexus.com .....
Beta-3 adrenergic receptors provide an anabolic stimulus. Beta-1 and Beta-2 adrenergic receptors provide a metabolically catabolic stimulus; essentially, they ramp-up the metabolism of the activated cell.
Humans have plenty of the Beta-1 and Beta-2 isoforms, and clenbuterol is a Beta-2 agonist. It's also a Beta-3 agonist, but we don't have Beta-3 adrenergic receptors in any appreciable amounts (that have been yet detected, at any rate). Hence, clen for humans is primarily catabolic.
to quote Dr. M from musclenexus.com .....
Beta-3 adrenergic receptors provide an anabolic stimulus. Beta-1 and Beta-2 adrenergic receptors provide a metabolically catabolic stimulus; essentially, they ramp-up the metabolism of the activated cell.
Humans have plenty of the Beta-1 and Beta-2 isoforms, and clenbuterol is a Beta-2 agonist. It's also a Beta-3 agonist, but we don't have Beta-3 adrenergic receptors in any appreciable amounts (that have been yet detected, at any rate). Hence, clen for humans is primarily catabolic.
Similar threads
